Home

Epifinity was launched during COVID-19 pandemic to apply current knowledge in epigenetics and virology in order to develop effective drugs against novel viruses. We all know that influenza viruses mutate every year and it is difficult for the scientists to develop an effective vaccine for current flu based on the previous year’s viral genome. However, these ever evolving flu viruses hijack the same epigenetic mechanisms in the host cell. So, we believe in developing effective medicines against the novel even yet non-existing flu-like viruses by manipulating their ability to hijack the host’s epigenetic mechanisms.

Our Vision

Epifinity was launched during COVID-19 pandemic to apply current knowledge in epigenetics and virology in order to develop effective drugs against novel viruses. We all know that influenza viruses mutate every year and it is difficult for the scientists to develop an effective vaccine for current flu based on the previous year’s viral genome. However, these ever evolving flu viruses hijack the same epigenetic mechanisms in the host cell. So, we believe in developing effective medicines against the novel even yet non-existing flu-like viruses by manipulating their ability to hijack the host’s epigenetic mechanisms.

About

We are scientists trained at the University of Toronto, University of California San Diego and Stanford with experience in drug discovery and development from large pharma (Takeda, Pfizer) and we want to make sure that next time when a new virus arises, our time to develop an effective vaccine or therapeutic will be weeks, not months to years. We are here to provide collaborative environment that enables breakthrough discoveries.

Contact

We are currently looking for

(i) companies to collaborate with

(ii) investors that share and believe in our vision to help it make a reality

Please email us info@epifinity.com to start a conversation.